Abstract
The recommended protocol for Tc99m tetrofosmin myocardial imaging suggests either a one- or two day imaging protocol so that stress and rest studies are sufficiently separated in time to allow optimum myocardium to background uptake ratios to differentiate between myocardial ischaemia and/or infarction. The biokinetic data for tetrofosmin suggest that no significant changes occur in myocardial distribution up to 180 minutes post injection. It is, therefore, necessary for two doses of the radiopharmaceutical and two separate studies to evaluate the myocardial status during stress and rest. This study assessed the differences between the 1 and 4 hour post injection SPET images obtained following peak exercise in 20 consecutively chosen patients. In addition, these images were compared to the rest images obtained on the following day after a second dose of the radiopharmaceutical was administered. In 4 patients, a one and four hour post injection study was also done during the rest phase. The results demonstrate significant changes in Tc-99m tetrofosmin distribution between the one hour and four hour post injection images. These differences are present during the stress as well as rest studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rigo P, Leclercq B, Itti R, et al. Technetium 99m-tetrofosmin myocardial imaging: a commparison with Thallium-201 and angiography. J Nucl Med 1994; 35: 587–93.
Sridhara B, Sochor H, Rigo P, et al. Myocardial single-photon emission computed tomographic imaging with technetium 99m tetrofosmin: stress-rest imaging with same-day and separate-day rest imaging. J Nucl Cardiol 1994; 1: 138–43.
Tamaki N, Takahashi N, Kawamoto M, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease. J Nucl Med 1994; 35: 594–600.
Braat BH, Leclercq B, Itti R, et al. Myocardial imaging with technetium-99m-tetrofosmin: comparison of one-day and two-day protocols. J Nucl Med 1994; 35: 1581–5.
Jain D, Wackers FJ Th, Mattera J, et al. Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993; 34: 1254–9.
Sinusas AJ, Shi QX, Saltzberg T, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischaemia. J Nucl Med 1994; 35: 664–71.
Nakajima K, Taki J, Shuke N, et al. Myocardial perfusion imaging and dynamic analysis with technetium-99m tetrofosmin. J Nucl Med 1993; 34: 1478–84.
Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993; 34: 222–7.
Sridhara BS, Braat S, Rigo P, et al. Comparison of myocardial perfusion imaging with Technetium-99m tetrofosmin versus thallium-201 in coronary artery disease. Am J Cardiol 1993; 72: 1015–9.
Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2,-bis[bis(2-ethoxyethyl) phosphino] ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34: 30–8.
Jones S, Hendel RC. Technetium-99m tetrofosmin: a new myocardial perfusion agent. J Nucl Med Technol 1993; 21: 191–5.
Liu P, Dawood F, Riley R, et al. Could the myocardial tracer Tc-MIBI be made to redistribute by altering its blood concentration? Circulation 1988; 78: 11–387.
Taillefer R, Primeau M, Costi P, et al. Technetium-99m-Sestamibi myocardial perfusion imaging in the detection of coronary artery disease: comparison between initial (1 hour) and delayed (3-hour) postexercise images. J Nucl Med 1991; 32: 1961–5.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pillay, M., Cox, P.H., Schönfeld, D.H.W. et al. Tc-99m tetrofosmin myocardial distribution 4 hours post injection. Int J Cardiac Imag 12, 127–135 (1996). https://doi.org/10.1007/BF01880744
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01880744